Company: GRCE
Filing Date: 2025-07-28
Form Type: DEF 14A
Source: 0001140361-25-027456
Chunk: 44

Company: Grace Therapeutics, Inc.
Filing Date: 2025-07-28
Form: DEF 14A
Chunk 44
---
 |    -324,621 |     |    -49,763 |
| Add: year-end value of equity awards granted in 2025 that are unvested and outstanding                        |     |     160,689 |     |     24,633 |
| Add: change in fair value (from prior year-end) of prior year equity awards that are unvested and outstanding |     |    -133,462 |     |    -26,690 |
| Add: fair market value of equity awards granted in 2025 and that vested in 2025                               |     |      81,126 |     |     12,436 |
| Add: change in fair value (from prior year-end) of prior year equity awards that vested in 2025               |     |    -113,690 |     |    -21,352 |
| Compensation Actually Paid for 2025                                                                           |     |     744,663 |     |    360,827 |

26

TABLE OF CONTENTS 27 TABLE OF CONTENTS Policies and Practices Related to the Grant of Certain Equity Awards Although we do not have a formal policy that requires us to award equity or equity-based compensation on specific dates, we generally issue equity awards to our employees, including our executive officers, annually in the first calendar quarter, and such awards are approved by our Board or Compensation Committee during the first quarter.In certain circumstances, including the hiring of an employee, the Board or Compensation Committee may approve grants to be effective at other times. Our Board and Compensation Committee does not take material nonpublic information into account when determining the timing and terms of such awards.Further, our Board and Compensation Committee has not timed, and does not plan to time, the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During the fiscal year ended March 31, 2025, no named executive officer was granted any stock options during the period beginning four business days before, and ending one business day after, the filing of a quarterly report on Form 10-Q or an annual report on Form 10-K, or the filing or furnishing of a current report on Form 8-K that disclosed material nonpublic information. 28

TABLE OF CONTENTS

DIRECTOR COMPENSATION The following table shows information with respect to the compensation of our non-employee directors who served on our Board during Fiscal Year 2025:

| Name               |     | Fees Earned 
  or Paid in 
        Cash 
         ($)